AFFILIATIONS
1 Department of Hematology, Institute of Hematology, and Center for High Altitude Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China
2 Department of Hematology, Institute of Hematology, and Center for High Altitude Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China
3 Department of Hematology, Institute of Hematology, and Center for High Altitude Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China
4 Hematology department, Mianyang central hospital,School of Medicine.University of Electronic Science and Technology of China, Mianyang, China, Mianyang, China
5 Hematology department, Mianyang central hospital,School of Medicine.University of Electronic Science and Technology of China, Mianyang, China, Mianyang, China
6 Department of Hematology, West China School of Medicine, Sichuan University, Sichuan University affiliated Chengdu Second People’s Hospital, Chengdu Second People’s Hospital, Chengdu, China., Chengdu, China
7 Department of Hematology, West China School of Medicine, Sichuan University, Sichuan University affiliated Chengdu Second People’s Hospital, Chengdu Second People’s Hospital, Chengdu, China., Chengdu, China
8 Department of Hematology, Institute of Hematology, and Center for High Altitude Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China
9 Department of Hematology, Institute of Hematology, and Center for High Altitude Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China
10 Department of Hematology, Institute of Hematology, and Center for High Altitude Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China
11 Department of Hematology, Institute of Hematology, and Center for High Altitude Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China
12 Department of Hematology, Institute of Hematology, and Center for High Altitude Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China
13 Department of Hematology, Institute of Hematology, and Center for High Altitude Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China
14 Department of Hematology, Institute of Hematology, and Center for High Altitude Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China
15 Department of Hematology, Institute of Hematology, and Center for High Altitude Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China
ABSTRACT
Aim:
Adult hemophagocytic lymphohistiocytosis (HLH) is a fatal hyperinflammatory syndrome. Etoposide–dexamethasone (ED) therapy is standard, but ED failure does not confirm irreversible disease. The JAK inhibitor ruxolitinib is increasingly used, but biomarkers predicting inflammatory reversibility and whether early laboratory recovery translates to survival benefit remain undefined. We developed the exploratory Ruxolitinib Inflammatory Recovery Score (RIRS) to characterize early inflammatory responses to ruxolitinib and evaluate links between early improvement, treatment timing, and overall survival (OS).
Methods:
This multicenter retrospective cohort enrolled consecutive adult (≥18 years) HLH patients receiving ruxolitinib-based therapy at 3 Chinese centers, 12/2022–03/2026. HLH was diagnosed by HLH-2004 criteria; overall survival (OS) was calculated from ruxolitinib initiation. ED response and early post-ruxolitinib laboratory improvement were assessed using seven biomarkers, with confirmed improvement defined by predefined criteria on days 7–14. Among ED-refractory patients, the exploratory 2-point Ruxolitinib Inflammatory Recovery Score (RIRS) assigned 1 point each for ferritin ≥2,650 ng/mL and fibrinogen ≤1.0 g/L (high RIRS: score 1–2). Linear mixed-effects models analyzed laboratory trajectories up to day 14. Cox models evaluated associations of RIRS and early improvement with OS, adjusted for age, ECOG status, and a baseline risk score (BUN, procalcitonin, albumin). Fine–Gray models treated pre-improvement death as a competing event; day-7 landmark analysis addressed immortal time bias. Interaction analyses tested modification of RIRS effects by the ED-to-ruxolitinib interval. Adjusted logistic regression examined relationships between categorized infection patterns and mortality.
Results:
Among 98 patients, 80.6% had EBV-associated HLH. Median follow-up was 364 days, median overall survival (OS) was 163 days, and 1-year OS was 40.0%. Broad response rates were 72.4% at day 7 and 70.4% at day 14. FDR-corrected mixed-effects models showed significant decreases in ferritin, soluble CD25, LDH, transaminases, procalcitonin, and CRP, whereas BUN and uric acid increased, consistent with inflammatory attenuation but persistent renal-metabolic stress.
Among 61 patients evaluable after etoposide–dexamethasone (ED), 21 were ED-responsive and 40 ED-refractory. Before ruxolitinib, ED-refractory patients had higher ferritin, soluble CD25, and LDH and lower platelet counts and fibrinogen. Fourteen of 40 patients (35.0%) improved within 7 days, and 17 (42.5%) achieved confirmed improvement during days 7–14. All early improvers remained responders, whereas only 3 of 26 early non-improvers subsequently improved.
Confirmed improvement rates were 32.0%, 87.5%, and 71.4% for scores of 0, 1, and 2, respectively, and 32.0% versus 80.0% for low versus high RIRS. The AUC was 0.711 (95% CI, 0.544–0.877), with an optimism-corrected C-statistic of 0.714. Each 1-point increase predicted first laboratory improvement in adjusted competing-risk analysis (sHR, 1.61; 95% CI, 1.01–2.56; P=0.045) but was not associated with death before improvement.
RIRS did not predict OS after adjustment for baseline systemic risk, age, and ECOG performance status (HR per point, 1.60; 95% CI, 0.83–3.11; P=0.161). Day-7 landmark analysis likewise found no association between early improvement and subsequent OS (HR for non-improver vs improver, 0.95; 95% CI, 0.36–2.50; P=0.916). The ED-to-ruxolitinib interval was not associated with OS (adjusted HR per day, 0.996; 95% CI, 0.944–1.052; P=0.895), with no significant RIRS-by-interval interactions. Persistent infection, but not new-onset infection, was associated with mortality (OR, 7.21; 95% CI, 1.83–48.12; P=0.013 vs OR, 2.32; 95% CI, 0.68–9.21; P=0.194). Severe nonhematologic toxicities were uncommon.
Conclusions:
ED-refractory HLH is not uniformly irreversible. The exploratory RIRS identifies patients likely to attain early laboratory recovery on ruxolitinib. Importantly, RIRS-predicted inflammatory reversibility and early biomarker improvement were not associated with longer survival, and treatment delay could not explain this response-survival disconnect. Persistent infection, rather than new infection, predicted mortality. Our findings indicate early inflammatory control and durable survival represent separate endpoints, discouraging use of short-term biomarker improvement as a survival surrogate.